Meeder Asset Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
VPM
VCM
DTC
Meeder Asset Management's AXSM Position: Q1 2026 in Review
Meeder Asset Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 30 shares — an estimated $5.48K sold.
Meeder Asset Management first reported a position in AXSM in Q4 2016 and held it in 19 quarters. The position peaked at $149K in Q2 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Meeder Asset Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
- Meeder Asset Management sold 30 Axsome Therapeutics shares in Q1 2026, an estimated $5.48K.
- Meeder Asset Management first reported a position in Axsome Therapeutics in Q4 2016 and held it in 19 quarters.
- Meeder Asset Management's Axsome Therapeutics position peaked at $149K in Q2 2020.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.